NuGen Medical Devices Inc. develops needle-free devices for subcutaneous drug delivery, centered on the InsuJet™ system for insulin administration and related consumables. Company news commonly covers commercialization of InsuJet and EziAutoJector® through distributors and pharmacy channels, product availability in markets such as France and the United Kingdom, and medical-device regulatory updates tied to national approvals and licensing.
NuGen updates also include research and development for prefilled and cartridge-based needle-free injection formats, patent activity for Ready-to-Fill COP/COC nozzles and the Prefilled Nozzle platform, annual financial results, and governance changes involving financial reporting functions.
NuGen Medical Devices Inc. (TSXV:NGMD) (OTCQB:NGMDF) announced plans to file for a new patent in the United States, Europe, and China. This patent aims to protect its needle-free injection device's refill design, enhancing safety and usability for insulin delivery. Initially patented in the Netherlands in October 2021, the new coverage targets key markets for insulin therapy. CEO Michael Wright emphasized that integrating the medicine vial into the device simplifies the injection process, benefiting chronic patients who require frequent injections.
NuGen Medical Devices has received approval from the TSX Venture Exchange to extend the expiry date and reduce the exercise price of 7,500,000 common share purchase warrants. The expiry date is extended by 12 months to September 30, 2023, and the exercise price is reduced from $0.70 to $0.40.
Additionally, the company’s private placement of 10% unsecured convertible debentures totaling $740,000 has received final acceptance, with no additional proceeds raised.
NuGen Medical Devices (TSXV:NGMD)(OTCQB:NGMDF) announced the appointment of Greg Gironda to its Advisory Board on September 16, 2022. With over 30 years in the pharmaceutical and biotechnology sectors, Gironda has extensive experience in needle-free technology and strategic planning. Previously, he played a pivotal role at EMD Serono, where he successfully launched the cool.click needle-free device alongside the Saizen growth hormone, increasing its market share significantly. This appointment demonstrates NuGen's commitment to enhancing its advisory team for developing innovative needle-free solutions.
NuGen Medical Devices Inc. has announced that its common shares received DTC full-service eligibility effective September 9, 2022. This milestone enhances the accessibility of its shares for U.S. investors, as they recently began trading on the OTCQB under the symbol NGMDF. DTC eligibility facilitates electronic clearing and settlement of transfers, marking a significant step in the company's growth strategy. NuGen specializes in needle-free technologies for medical delivery, with products like InsuJet™ and PetJet™, targeting diabetes and veterinary medicine.
NuGen Medical Devices Inc. has commenced trading on the OTCQB under the symbol NGMDF, effective July 27, 2022. This marks a significant milestone, enhancing the accessibility for American investors. The company continues to trade on the TSX Venture Exchange under the symbol NGMD. NuGen is also awaiting approval for DTC eligibility, facilitating electronic settlement and transfer of shares in the U.S. The company specializes in needle-free medical devices, including the InsuJet™ and PetJet™, targeting diabetes, veterinary medicine, and vaccines.